Article
BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Oct 2017
Niessner Heike, Sinnberg Tobias, Kosnopfel Corinna, Smalley Keiran S M, Beck Daniela, Praetorius Christian, Mai Marion, Beissert Stefan, Kulms Dagmar, Schaller Martin, Garbe Claus, Flaherty Keith T, Westphal Dana, Wanke Ines, Meier Friedegund
Abstract excerpt
Purpose: NRAS mutations in malignant melanoma are associated with aggressive disease requiring rapid antitumor intervention, but there is no approved targeted therapy for this subset of patients. In clinical trials, the MEK inhibitor (MEKi) binimetinib displayed modest antitumor activity, making combinations a requisite. In a previous study, the BRAF inhibitor (BRAFi) vemurafenib was shown to induce endoplasmic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.